On October 22, 2024, Alvotech and Teva announced that SELARSDI (ustekinumab-aekn) received FDA approval for a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. We previously reported that SELARSDI was approved by the FDA for 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection. This new presentation allows for SELARSDI to expand its label to align with the indications of the reference product STELARA® (ustekinumab). Thomas Rainey, Senior Vice President, U.S. Biosimilars, stated “This development allows us to serve patients battling gastrointestinal diseases as the U.S. launch of SELARSDI approaches in early 2025.”
The post Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar appeared first on Big Molecule Watch.